AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31830404 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercises (three weekly sessions including meditation, breathing control, and slow body movements)
Number of subjects: 70
Study 31830404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 30567838 — intervention group
Group type: EXPERIMENTAL
Intervention: Watson's Human Caring Model nursing care provided at home for 8 weeks
Number of subjects: 158
Study 30567838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study 26260878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath-based trunk exercises
Number of subjects: 22
Study 26260878 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises (control group)
Number of subjects: 22
Study 24149088 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection (any HPV)
Number of subjects: 2519
Study 24149088 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV infection
Number of subjects: 2519
Study 24149088 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional HPV genotype infection
Number of subjects: 2519
Study 24149088 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent HPV infection
Number of subjects: 2519
Study 24149088 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently cleared HPV infection
Number of subjects: 2519
Study 22424859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg BID
Number of subjects: 0
Study 22424859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19645217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac formulations with sample size N = 12
Number of subjects: 12
Study 19645217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac formulations with sample size N = 24
Number of subjects: 12
Study 19645217 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials for all pharmacokinetic parameters
Number of subjects: 12
Study 19645217 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of 0.8
Number of subjects: 12
Study 19645217 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 12
Study 18717761 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid-enriched nutrient-mixture (AEN group)
Number of subjects: 112
Study 18717761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 112
Study 16210020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 micromol/L FF-MAS
Number of subjects: 218
Study 16210020 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micromol/L FF-MAS
Number of subjects: 218
Study 16210020 — intervention group
Group type: COMPARATOR
Intervention: 0.2% recombinant human albumin (vehicle control)
Number of subjects: 218
Study 16210020 — intervention group
Group type: COMPARATOR
Intervention: Medium alone (control)
Number of subjects: 218
Study 16210020 — intervention group
Group type: COMPARATOR
Intervention: All groups (including controls)
Number of subjects: 218
Study 11809164 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark-based segmentation method applied to MRI scans of patients with vascular dementia
Number of subjects: 20
Study 11809164 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based segmentation method applied to MRI scans of healthy elderly subjects
Number of subjects: 20
Study 10511914 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method of in-vivo estimation of sound velocity in the lens during 2 to 3 seconds.
Number of subjects: 0
Study 10511914 — intervention group
Group type: COMPARATOR
Intervention: Customary method of IOL power calculation.
Number of subjects: 0
Study 7854531 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy (DMD) patients
Number of subjects: 19
Study 7854531 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 1682177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose acetyl salicylic acid (ASA) 75 mg/day for 10 days
Number of subjects: 20
Study 1682177 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for 10 days
Number of subjects: 20
Study 1682177 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to ASA after conventional therapy
Number of subjects: 20
Study 1682177 — intervention group
Group type: COMPARATOR
Intervention: Crossover to conventional therapy after ASA
Number of subjects: 20
Study 6291355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (Combantrin) at a dose of 20 mg/kg body weight for 1‐3 days
Number of subjects: 185
Study 6291355 — intervention group
Group type: COMPARATOR
Intervention: Pyrantel pamoate (Combantrin)
Number of subjects: 185
Study 31498389 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 22
Study 31498389 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 30453747 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute mindful breathing
Number of subjects: 40
Study 30453747 — intervention group
Group type: COMPARATOR
Intervention: 20-minute supportive listening
Number of subjects: 40
Study 28081888 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized sexual health survey with decision support for STI testing
Number of subjects: 728
Study 28081888 — intervention group
Group type: COMPARATOR
Intervention: Usual care without decision support
Number of subjects: 728
Study 28081888 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized sexual health survey with decision support for STI testing among asymptomatic patients
Number of subjects: 728
Study 28081888 — intervention group
Group type: COMPARATOR
Intervention: Usual care without decision support among asymptomatic patients
Number of subjects: 728
Study 26467573 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice via the Internet based on current PA plus diet (Level 1, L1)
Number of subjects: 1607
Study 26467573 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice via the Internet based on PA plus diet and phenotype (Level 2, L2)
Number of subjects: 1607
Study 26467573 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice via the Internet based on PA plus diet, phenotype, and genotype (Level 3, L3)
Number of subjects: 1607
Study 26467573 — intervention group
Group type: EXPERIMENTAL
Intervention: Advised to increase PA (all personalized groups)
Number of subjects: 1607
Study 26467573 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonpersonalized advice, Level 0, L0)
Number of subjects: 1607
Study 23529173 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 33500
Study 23529173 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 33500
Study 23529173 — intervention group
Group type: COMPARATOR
Intervention: chlorthalidone
Number of subjects: 33500
Study 21817186 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine plus lopinavir/ritonavir (533/133 mg twice daily)
Number of subjects: 122
Study 21817186 — intervention group
Group type: COMPARATOR
Intervention: zidovudine/lamivudine plus lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 122
Study 19927228 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing treatment options for osteoporosis and fracture prevention, including potent antiresorptive and anabolic agents.
Number of subjects: 0
Study 17689173 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks
Number of subjects: 37
Study 17689173 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 37
Study 15104769 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive approach (angiography before 48 hours)
Number of subjects: 1078
Study 15104769 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive approach (angiography after 48 hours)
Number of subjects: 1078
Study 11806392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpedicular grafting (TPG)
Number of subjects: 21
Study 11806392 — intervention group
Group type: COMPARATOR
Intervention: Non-transpedicular grafting (NTPG)
Number of subjects: 21
Study 9777834 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (1 microg bolus every 2 h when diuresis > 300 mL/h)
Number of subjects: 97
Study 9777834 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 97
Study 9777834 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study 7826054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet
Number of subjects: 60
Study 7826054 — intervention group
Group type: COMPARATOR
Intervention: Regular 1300‐kcal weight‐reducing diet
Number of subjects: 60
Study 7826054 — intervention group
Group type: COMPARATOR
Intervention: Lactovegetarian diet and Regular diet
Number of subjects: 60
Study 3182117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenticonazole 2% lotion, applied once daily for three weeks
Number of subjects: 46
Study 3182117 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole 1% lotion, applied once daily for three weeks
Number of subjects: 46
Study 29463461 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol and 4 mg oral ondansetron
Number of subjects: 122
Study 29463461 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol and oral placebo
Number of subjects: 122
Study 29463461 — intervention group
Group type: COMPARATOR
Intervention: Inhaled saline solution placebo and 4 mg oral ondansetron
Number of subjects: 122
Study 27590372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation hemostasis (Group A)
Number of subjects: 207
Study 27590372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scalpel hemostasis (Group B)
Number of subjects: 207
Study 27590372 — intervention group
Group type: COMPARATOR
Intervention: Suture technique hemostasis (Group C)
Number of subjects: 207
Study 24321456 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ST information presented alone
Number of subjects: 571
Study 24321456 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ST information presented with pro-ST information
Number of subjects: 571
Study 24321456 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking information
Number of subjects: 571
Study 24321456 — intervention group
Group type: EXPERIMENTAL
Intervention: Product trials
Number of subjects: 571
Study 23769278 — intervention group
Group type: EXPERIMENTAL
Intervention: PDD-FURS
Number of subjects: 30
Study 23769278 — intervention group
Group type: COMPARATOR
Intervention: WL-FURS
Number of subjects: 30
Study 23769278 — intervention group
Group type: COMPARATOR
Intervention: CTU
Number of subjects: 30
Study 20646533 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a combined with estradiol valerate 0.5 mg and dydrogesteronea 5 mg daily
Number of subjects: 70
Study 20646533 — intervention group
Group type: COMPARATOR
Intervention: GnRH‐a
Number of subjects: 70
Study 18329013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (200 microg/m(3))
Number of subjects: 16
Study 18329013 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 16
Study 18329013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (100 microg/m(3))
Number of subjects: 16
Study 16350715 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele of Taq I VDR gene
Number of subjects: 206
Study 16350715 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes: aa, bb, TT of VDR gene
Number of subjects: 206
Study 11868798 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB and oral spironolactone 100 mg twice daily
Number of subjects: 26
Study 11868798 — intervention group
Group type: COMPARATOR
Intervention: AmB alone
Number of subjects: 26
Study 10594411 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy and tracheal intubation (n = 18)
Number of subjects: 34
Study 10594411 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway insertion (n = 16)
Number of subjects: 34
Study 7781578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint manipulation
Number of subjects: 0
Study 7781578 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 7781578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint manipulation with EMLA cream
Number of subjects: 0
Study 2083605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus clemastine
Number of subjects: 20
Study 2083605 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus clemastine
Number of subjects: 20
Study 7418570 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (2000 rad Co60)
Number of subjects: 66
Study 7418570 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Co60 therapy + Methotrexate + 5-Fluorouracil
Number of subjects: 66
Study 7418570 — intervention group
Group type: COMPARATOR
Intervention: Co60 therapy alone
Number of subjects: 66
Study 7418570 — intervention group
Group type: COMPARATOR
Intervention: Surgery without previous radiotherapy
Number of subjects: 66
Study 31750786 — intervention group
Group type: COMPARATOR
Intervention: Multimodal treatment (3 times a week for 6 weeks)
Number of subjects: 61
Study 31750786 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention (6 weeks) based on subgroup characteristics
Number of subjects: 61
Study 31750786 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 61
Study 31750786 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention in 'weak and pronated foot' subgroup
Number of subjects: 61
Study 31750786 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention in 'weak and tight' subgroup
Number of subjects: 61
Study 31750786 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention in 'strong' subgroup
Number of subjects: 61
Study 31182139 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril) added to standard of care
Number of subjects: 280
Study 31182139 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (placebo)
Number of subjects: 280
Study 28917232 — intervention group
Group type: EXPERIMENTAL
Intervention: CFMO
Number of subjects: 12
Study 28917232 — intervention group
Group type: EXPERIMENTAL
Intervention: CFSO
Number of subjects: 12
Study 27276835 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutritional Therapy (MNT) with Self Blood Glucose Monitoring (SBGM)
Number of subjects: 60
Study 27276835 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 23551127 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine early tirofiban treatment
Number of subjects: 286
Study 23551127 — intervention group
Group type: COMPARATOR
Intervention: Deferred provisional tirofiban treatment
Number of subjects: 286
Study 21238859 — intervention group
Group type: EXPERIMENTAL
Intervention: King County restaurants (intervention group)
Number of subjects: 14
Study 21238859 — intervention group
Group type: COMPARATOR
Intervention: Control locations (non-intervention group)
Number of subjects: 14
Study 19130293 — intervention group
Group type: EXPERIMENTAL
Intervention: SSKI (Saturated Solution Potassium Iodide)
Number of subjects: 0
Study 19130293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17117398 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroPsychological Training (TNP) plus cholinesterase inhibitors
Number of subjects: 59
Study 17117398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors alone
Number of subjects: 59
Study 17117398 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59
Study 14757591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined psychotherapy (8 sessions of cognitive behavior therapy) plus pharmacotherapy (citalopram)
Number of subjects: 109
Study 14757591 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 109
Study 11158406 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rHuEpo) therapy for 3 months
Number of subjects: 26
Study 11158406 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rHuEpo) therapy for 1 year
Number of subjects: 26
Study 9547958 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulators (normal participants feigning memory impairment)
Number of subjects: 40
Study 9547958 — intervention group
Group type: EXPERIMENTAL
Intervention: Coin-in-the-hand test with autobiographical interview
Number of subjects: 40
Study 9547958 — intervention group
Group type: COMPARATOR
Intervention: Normal participants (performing honestly)
Number of subjects: 40
Study 9547958 — intervention group
Group type: COMPARATOR
Intervention: Memory-impaired participants
Number of subjects: 40
Study 7519005 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 60 mg/d
Number of subjects: 16
Study 7519005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3219752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 24
Study 3219752 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin plus gentamicin
Number of subjects: 24
Study 3219752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 30081055 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU of oxytocin
Number of subjects: 20
Study 30081055 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 28387017 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy in Multisensory Environment (MT in MSE)
Number of subjects: 42
Study 28387017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory Environment (MSE) alone
Number of subjects: 42
Study 28387017 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT) alone
Number of subjects: 42
Study 28387017 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 42
Study 25707380 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 11
Study 23496822 — intervention group
Group type: EXPERIMENTAL
Intervention: BMR with BET (behaviour-oriented)
Number of subjects: 214
Study 23496822 — intervention group
Group type: COMPARATOR
Intervention: BMR with SET (function-oriented)
Number of subjects: 214
Study 20852958 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (anxiolytic medication)
Number of subjects: 60
Study 20852958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication administered for anxiety reduction)
Number of subjects: 60
Study 18635724 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 mg THC
Number of subjects: 14
Study 18635724 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 mg THC
Number of subjects: 14
Study 18635724 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 mg and 17 mg THC
Number of subjects: 14
Study 17065274 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-hour infusion of cetuximab at doses of 50, 100, 250, 400, or 500 mg/m2 followed by weekly 1-hour infusions of cetuximab at a fixed dose of 250 mg/m2
Number of subjects: 40
Study 12921449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfamil AR
Number of subjects: 104
Study 10752747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblasts from patients with hypertrophic burn scars (HBSs)
Number of subjects: 0
Study 10752747 — intervention group
Group type: EXPERIMENTAL
Intervention: HBS fibroblasts (unstimulated)
Number of subjects: 0
Study 10752747 — intervention group
Group type: EXPERIMENTAL
Intervention: HBS fibroblasts (serum stimulated)
Number of subjects: 0
Study 10752747 — intervention group
Group type: EXPERIMENTAL
Intervention: HBS fibroblasts (serum and interferon‐gamma stimulated)
Number of subjects: 0
Study 10752747 — intervention group
Group type: COMPARATOR
Intervention: Control fibroblasts (unstimulated)
Number of subjects: 0
Study 10752747 — intervention group
Group type: COMPARATOR
Intervention: Control fibroblasts (serum stimulated)
Number of subjects: 0
Study 10752747 — intervention group
Group type: COMPARATOR
Intervention: Control fibroblasts (serum and interferon‐gamma stimulated)
Number of subjects: 0
Study 9558629 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion product otoacoustic emission (DPOAE) measurement in subjects with industrial noise-induced hearing loss.
Number of subjects: 0
Study 9558629 — intervention group
Group type: COMPARATOR
Intervention: Distortion product otoacoustic emission (DPOAE) measurement in subjects with presbycusis.
Number of subjects: 0
Study 9558629 — intervention group
Group type: COMPARATOR
Intervention: Distortion product otoacoustic emission (DPOAE) measurement in subjects with hearing impairment caused by gentamycin.
Number of subjects: 0
Study 1604987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 100
Study 1604987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2437086 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus RT (arm A: 36 patients)
Number of subjects: 80
Study 2437086 — intervention group
Group type: COMPARATOR
Intervention: CT alone (arm B: 44 patients)
Number of subjects: 80
Study 2437086 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus RT (arm A)
Number of subjects: 80
Study 2437086 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus RT (arm A) and CT alone (arm B)
Number of subjects: 80
Study 29354928 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with HAART (zidovudine, lamivudine, nevirapine, efavirenzone)
Number of subjects: 100
Study 29354928 — intervention group
Group type: COMPARATOR
Intervention: Simple HAART
Number of subjects: 100
Study 26658446 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls made by paramedics to physician-investigators
Number of subjects: 4458
Study 26658446 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for screen failure
Number of subjects: 4458
Study 26658446 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for phone informed consent
Number of subjects: 4458
Study 23657879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular fibrinogen
Number of subjects: 200
Study 23657879 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 200
Study 23780378 — intervention group
Group type: EXPERIMENTAL
Intervention: ILP (Interstitial laser photocoagulation)
Number of subjects: 44